EntreMed initiates Ph II Panzem study in HRPC

17 September 2006

EntreMed, a US clinical-stage pharmaceutical company developing therapeutics for cancer and inflammatory diseases, has commenced a multicenter Phase II study with its lead drug candidate, Panzem NCD (2-methoxyestradiol), in patients with hormone-refractory prostate cancer.

Patients with evidence of progressive metastatic disease or known metastatic disease and rising prostate-specific antigen, during or after treatment with a taxane-based regimen, are expected to be enrolled in the study, to assess the drug's antitumor activity, safety and pharmacokinetics.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight